Alexander Vos

Alexander Vos is an experienced biotech leader with 30 years in the industry and a successful track record in biopharmaceuticals, particularly in orphan and rare diseases and cell & gene therapy.

He began his career at McKinsey & Co., then joined Genzyme Therapeutics Europe, where he held several executive roles, including leading a JV for Pompe’s Disease treatment. From 2000 to 2004, he was CEO of MediService AG, which was successfully sold to Galenica AG. He then joined PAION AG as Deputy-CEO and COO. In 2010, he became CEO of PharmaCell BV, turning it into a leading CMO for cell and gene therapy before its sale to Lonza in 2017. Subsequently, he served as CEO of VarmX and VectorY, raising EUR 50 million and EUR 30 million respectively, and advancing both companies towards IND. He now serves on the boards of several biotech companies and is a Venture Partner at BioGeneration Ventures. Alexander Vos is skilled in strategy development, investor relations, operations management, biotechnology, licensing, M&A, and marketing. He holds an MS in Pharmacy and Pharmacology from the University of Amsterdam and an MBA from Stanford University. His focus on transactional, value-oriented outcomes has resulted in two successful exits for investors.